Regeneron Pharmaceuticals (REGN) presents a compelling bullish thesis with a trailing P/E of 14.73, market capitalization of $63.21 billion, TTM revenue of $14.92 billion (up 19% YoY), and EPS of $40.94. The stock trades at a forward P/E of 13.39 with a robust 29.6% profit margin and low beta of 0.296, indicating strong earnings power and defensive characteristics relative to the broader market.
Key catalysts include sustained momentum in flagship products like Eylea and Dupixent, ongoing pipeline expansion in oncology and immunology, and analyst consensus target of $833.31 (implying ~40% upside from recent levels near $614). Quarterly revenue growth of 19% and institutional ownership exceeding 92% underscore earnings momentum and long-term conviction from major investors.
Risks include regulatory hurdles for new approvals, intense competition in the biotech space, and potential macro headwinds from healthcare policy changes. These are mitigated by Regeneron's diversified revenue base, high operating margins of 20.7%, and proven track record of innovation, with the company maintaining a strong balance sheet and consistent profitability.
Get Deeper Analysis
Ask Theo anything about REGN — earnings, valuation, technicals, or portfolio fit.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Fundamental Snapshot
Revenue
14.9196B
EBITDA
4.3828B
Gross Profit
6.5475B
Operating Margin
20.7%
Profit Margin
29.6%
ROE
14.5%
Book Value
$308.32
Beta
0.296
52-Wk High
$818.9
52-Wk Low
$473.89
Avg Volume
1.067M
PEG Ratio
1.07
Trading Data
Open
$624.17
Previous Close
$611.34
Day Range
$610.95 – $628.9
Volume
1.1907M
Shares Outstanding
103.022M
Analyst Target
$833.31
Frequently Asked Questions
What is Regeneron Pharmaceuticals' business model?
Regeneron is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases, primarily through its proprietary VelociSuite technologies. It generates revenue from product sales (notably Eylea and Dupixent) and collaborations, with TTM revenue of $14.92 billion and a 29.6% profit margin.
What are Regeneron's main revenue sources?
The company's primary revenue comes from sales of Eylea (for eye diseases) and Dupixent (for inflammatory conditions), supplemented by collaboration revenue. TTM revenue reached $14.92 billion with 19% YoY growth, and EPS stands at $40.94.
What are Regeneron's key competitive advantages?
Regeneron benefits from its innovative VelociGene and VelocImmune platforms enabling rapid drug development, a strong patent portfolio, and high barriers in biotech. It boasts a low beta of 0.296, 92.1% institutional ownership, and a forward P/E of 13.39, reflecting market recognition of its R&D edge.
What are the main risks for REGN investors?
Key risks include regulatory approval delays, competition from biosimilars, and potential reimbursement pressures in healthcare. These are offset by the company's 20.7% operating margin, diversified pipeline, and analyst target price of $833.31 providing a buffer against volatility.
What is the growth outlook for Regeneron?
Regeneron shows strong growth potential with 19% quarterly revenue growth, pipeline expansion in oncology/immunology, and analyst ratings favoring buys (16 buy ratings). The stock's 52-week range of $482.36-$818.90 and dividend yield of 0.6% support a positive long-term outlook amid biotech sector tailwinds.
